Enzymatic Liver Function Capacity Correlates with Disease Severity of Patients with Liver Cirrhosis: A Study with the LiMAx Test
Assessment and quantification of actual liver function is crucial in patients with chronic liver disease to monitor disease progression and predict individual prognosis. Mathematical models, such as model for end-stage liver disease, are used for risk stratification of patients with chronic liver disease but do not include parameters that reflect the actual functional state of the liver.
We aimed to evaluate the potential of a 13C-based liver function test as a stratification tool by comparison with other liver function tests and clinical parameters in a large sample of healthy controls and cirrhotic patients.
We applied maximum liver function capacity (LiMAx) to evaluate actual liver function in 347 patients with cirrhosis and in 86 controls.
LiMAx showed strong negative correlation with Child-Pugh Score (r = −0.707; p < 0.001), MELD (r = −0.686; p < 0.001) and liver function tests. LiMAx was lower in patients with liver cirrhosis compared to healthy controls [99 (57–160) µg/kg/h vs. 412 (365–479) µg/kg/h, p < 0.001] and differed among Child-Pugh classes [a: 181 (144–227) µg/kg/h, b: 96 (62–132) µg/kg/h and c: 52 (37–81) µg/kg/h; p < 0.001]. When stratified patients according to disease severity, LiMAx results were not different between cirrhotic patients and cirrhotic patients with transjugular intrahepatic portosystemic shunt.
LiMAx appears to provide reliable information on remnant enzymatic liver function in chronic liver disease and allows graduation of disease severity.
KeywordsLiMAx Cirrhosis Liver function Liver function tests Disease severity Surrogate marker
This study was funded in part by the European Union’s 7th Framework Programme, d-LIVER Grant agreement no. 287596.
Conflict of interest
Martin Stockmann is the inventor of the LiMAx test and has capital interest in Humedics, the company marketing the LiMAx test. In addition he is steering board member for the d-LIVER Project (funded by the European Commission Framework Program). Maximilian Jara and James Orr disclose receiving research Grants in order of the d-LIVER European Commission Framework Program (Grant agreement no. 287596). Remaining authors who have taken part in this study declared that they do not have anything to disclosure regarding funding or conflict of interest with respect to this manuscript.
- 11.Parra D, Gonzalez A, Garcia-Villarreal L, Martinez JA. Methodological characterization of the 2-keto [1-13C]isocaproate breath test to measure in vivo human mitochondrial function: application in alcoholic liver disease assessment. Alcohol Clin Exp Res.. 2003;27:1293–1298.PubMedCrossRefGoogle Scholar